Chief Executive Officer, Chairman of the Board of Directors- George W. Evans, JD, MBA;
George Evans has more than a quarter-century of experience in the Pharmaceutical industry, including holding a number of positions at Pfizer. He wrapped up his career there as General Counsel for the worldwide prescription drug unit and a member of the unit's leadership team. During his time at Pfizer, Mr. Evans acquired experience in all aspects of the pharmaceutical business, from early-stage research to end-of-life-cycle strategies, and he played a key role in negotiating several major transactions. In addition to his direct industry experience, Mr. Evans has a wealth of experience in building and integrating organizations while maintaining the highest levels of performance. Mr. Evans was a member of the Editorial Advisory Board of the Food and Drug Law Journal and the Finance Committee of the Food and Drug Law Institute and a member of the Board of the New York City Bar Fund. He is currently a member of the Advisory Board of South Boston, Virginia's Founders College, a liberal arts institution whose mission is to provide an educational experience based on a carefully integrated core of great ideas. He is a graduate of Williams College and Columbia University’s Law and Business schools.

President, Chief Scientific Officer, Board of Directors - Dr. Krishna Menon
RCM, PhD, VMD - Dr. Krishna Menon has more than 35 years in drug development for academia and industry. Originally trained as a veterinary surgeon, Menon began his career as Chief Government Veterinarian for a major Parish in Jamaica. He segued to a three-year stint as Director of Agriculture for the Cayman Islands, in the British Caribbean and, in 1982, moved to the Dana Farber Cancer Research Institute, where he worked under the direction of Nobel Laureate Dr. Tom Frye. Two years later, he earned his PhD in Pharmacology from Harvard University. Menon's PhD work focused on anti-folate therapy of various cancers. Menon was a Research Scientist at Dana Farber from 1985 to 1990 and Senior Research Scientist, In Vivo Research (Cancer), at Bayer Pharmaceuticals (Miles Laboratories) from 1991 to 1993. After a year operating his own veterinary oncology and drug development consultancy practice, Menon was tapped Group Leader, Cancer In Vivo Research and Clinical Development, for Eli Lilly (1995-2001), where he played a key role in lead selection and pre-clinical development of Gemzar and Alimta which in 2006 had over 2.1 billion dollars ($2,100,000,000) in sales, and is a co-developer of another seven compounds currently in late-stage clinical development. In 1999, Lilly honored Menon with the President's Recognition Award, an award not bestowed annually but rather on only special occasions.

Chief Financial Officer, Board of Directors- Leo Ehrlich, CPA
Served as Chief Financial Officer (CFO) of Cellceutix Pharma since inception in June 2007. Following the acquisition, he was appointed CFO and a director. From October 8, 1999 to the present time, Mr. Ehrlich has been a director at StatSure Diagnostic Systems, Inc. and has held different executive officer positions at that company including CEO, President, and his current title of CFO. Mr. Ehrlich was also CFO and a director of Nanoviricides, Inc. from June 1, 2005. until May 2007. Mr. Ehrlich is a Certified Public Accountant and received his BBA from Bernard Baruch College of the City University of New York.